NFL BIOSCIENCES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.1 EUR | -1.18% |
|
+8.47% | +45.83% |
| 04-12 | Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... |  |
| 04-12 | NFL Biosciences: successful capital increase | CF |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Capitalization 1 | 17.23 | 17.23 | - |
| Enterprise Value (EV) 1 | 17.23 | 17.03 | 14.63 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | 86.1 x | - | - |
| EV / Revenue | 86.1 x | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | -4.52 x | -3.41 x | -1.9 x |
| FCF Yield | -22.1% | -29.4% | -52.6% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 8,107 | 8,107 | - |
| Reference price 2 | 2.125 | 2.125 | 2.125 |
| Announcement Date | 24-03-29 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net sales 1 | 0.2 | - | - |
| EBITDA | - | - | - |
| EBIT 1 | -4.23 | -4.7 | -7.8 |
| Operating Margin | -2,115.1% | - | - |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | - | - | - |
| Free Cash Flow 1 | -3.3 | -5 | -7.7 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 24-03-29 | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 2.3 | 0.2 | 2.6 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow 1 | -3.3 | -5 | -7.7 |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets | - | - | - |
| Book Value Per Share | - | - | - |
| Cash Flow per Share 2 | -0.7000 | -0.9000 | -1.500 |
| Capex 1 | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | 24-03-29 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.125
EUR
Average target price
4.2
EUR
Spread / Average Target
+97.65%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +45.83% | 18.59M | |
| +4.15% | 111B | |
| +11.52% | 105B | |
| -12.94% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.19% | 16.96B | |
| +3.34% | 13.7B | |
| +37.41% | 12.45B |
- Stock Market
- Equities
- ALNFL Stock
- Financials NFL Biosciences
